Opinion: STAT+: Why does the FDA want to stop improving medicines via patent ‘areas of concern’?
It’s hardly unprecedented for one federal agency to encroach on another’s turf. But the latest intra-executive-branch…
Category: Opinions+
Opinion: STAT+: Rewriting the playbook for digital therapeutics
The acceleration of investment in digital health and adoption of health-related apps triggered by the…
.jpg)
Opinion: STAT+: Combating the burnout bottleneck among clinical research workers
Health care professionals of all stripes were battling burnout and mental illness before the pandemic…
Opinion: STAT+: Digital clinical trials can personalize patient engagement, accelerate therapy development
Biopharmaceutical companies were conducting more than 9,000 clinical trials in the U.S. in March 2020…
Opinion: STAT+: A 10-point plan for sustaining the biopharma industrial base for a more secure nation
Covid-19 has underscored the critical role the biopharma industrial base plays in the U.S.’s national…
Opinion: STAT+: Bringing clarity and consistency to CMS’s hospital price transparency rule will be a win for all
The Centers for Medicare and Medicaid Services’ (CMS) price transparency rule requiring U.S. hospitals to…
Opinion: STAT+: Viruses, variants, and the business of health care: Preparing for another wave now and the years ahead
We’re in a new phase of the Covid-19 pandemic in which new mutations will have…
Opinion: STAT+: Human-centered design can boost clinical trial recruitment, retention
By disrupting the clinical trials process, the Covid-19 pandemic has served as a tipping point…
Opinion: STAT+: Stifling biopharma mergers would kill the innovation economy that generates new therapies
The headlines speak of a biotech boom with news of company launches, oversubscribed private financings,…
Opinion: STAT+: SARS-CoV-2 brought the world to its knees. Its digital twin is helping bring us back
“Bad news wrapped up in protein.” That’s how the late Nobel Laureate Sir Peter Medawar…
Opinion: STAT+: The many benefits of expanding the reach of state all-payer claims databases
Appointments to the newly created State All Payer Claims Databases Advisory Committee in March were…
Opinion: STAT+: ‘Induced proximity’ is why I am optimistic about treating undruggable diseases
So-called undruggable proteins — those that supposedly can’t be targeted by pharmaceuticals — represent a…
Opinion: STAT+: The pharma industry needs to measure patient experience from the patients’ perspectives
The relationship between clinical outcomes and the patient experience — the sum of all of…
Opinion: STAT+: Faster approval of complex generics is central to affordable, equitable care
The push to improve Americans’ use of effective and less-expensive generic medications is getting a…
Opinion: STAT+: How the FDA’s ‘master plan’ will affect NIH funding for digital medicine projects
The term B.C. took on a new meaning — Before Covid — last year when…
Opinion: STAT+: Improving health care means improving data diversity. Federated learning can help
Many companies are developing innovative artificial intelligence solutions for health care. Too often, though, these…
Opinion: STAT+: Investment in antimicrobials was up in 2020, but much work remains
The emergence of the Covid-19 pandemic generated renewed interest in the development of vaccines and…
Opinion: STAT+: More pharma companies should make the move toward B Corps sustainability
The gradual global shift towards sustainability, with an increased focus on climate change and environmental…
Opinion: What’s next for diagnostic labs, a ‘bright spot’ during Covid-19?
As U.S. diagnostic labs began confronting the Covid-19 pandemic in early March 2020, they faced…
Opinion: FDA: make medical apps reliable, not risky
The fear of Covid-19 catapulted symptom checkers from the periphery of public attention to the…
Opinion: STAT+: The FDA should embrace remote and automated drug inspection technology
While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections…
Opinion: STAT+: Developers of microbiome-based drugs face challenges. There are ways to overcome them
Manipulating the human microbiome appears to be an effective approach for treating a range of…
Opinion: STAT+: Rethinking triage in an era of vaccine nationalism
Just about every schoolchild learns that Napoleon Bonaparte was a small man. But few know…